V-Wave, an Israel-based company that has developed a minimally invasive implanted shunt device for treating patients with severe symptomatic heart failure has raised $98 million in a Series C financing round, the company announced Tuesday.
Dr. Andrew ElBardissi, a partner in the lead investor in the Series C round, called the V-Wave Shunt a "novel technology that modifies the physiology of heart failure by reducing left atrial and pulmonary artery pressures in a continuous, real-time manner without any intervention by the patient or a caregiver."
Follow Israel Hayom on Facebook and Twitter
V-Wave Chairman Dr. Frank Litvack added, "With more than 26 million patients suffering HF globally and more than 6 million in the US, there is a huge unmet clinical and economic need for simple, cost effective new therapies."
The financing will go to clinical studies of the V-Wave Shunt and to obtain FDA clearance, subject to agency review.
